Business Wire

Careismatic Brands Launches “19 Days of Gratitude” Global Campaign to Support Nurses and the DAISY Foundation

Share

Careismatic Brands, the world’s largest designer and manufacturer of medical apparel, today announced the launch of a global tribute and charitable fundraising campaign, “19 Days of Gratitude,” spotlighting the heroism of nurses as they continue to battle COVID-19 on the front lines. Launching in a year that the World Health Organization has deemed “The International Year of The Nurse and Midwife,” and timed to the 200th anniversary of Florence Nightingale’s birth, the new campaign will celebrate nurses by revealing 19 stories that showcase frontline nurses from around the world over 19 consecutive days. The campaign will debut on careismatic.com/TributeToCourage and across Careismatic’s various social and digital channels, to celebrate the nursing community and raise money for the DAISY (Diseases Attacking the Immune System) Foundation, a worldwide organization recognizing the incredible work and sacrifice of nurses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005263/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Medical apparel manufacturer, Careismatic Brands, launches global campaign to pay tribute to nurses and raise funds for the DAISY Foundation (Graphic: Business Wire)

The campaign will kick off with a powerful tribute video “In The Year of The Nurse – A Tribute to Courage,” shot and produced by Hollywood creative agency Mob Scene. The video features a reimagined recording of George Harrison’s classic song, “Give Me Love (Give Me Peace on Earth)” from Grammy Award-winning music producer Rob Cavallo (former Chairman of Warner Bros. Records, whose accolades include 1988 Producer of the Year; 2005 Record of the Year for Green Day’s Boulevard of Broken Dreams;and selling in excess of 160 million records worldwide). Cavallo’s version of “Give Me Love (Give Me Peace on Earth)” features children singing from home and is designed to recognize and uplift health care professionals during this pandemic.

“Health care professionals are selfless people who are putting themselves on the line to save people’s lives during this COVID-19 crisis and this campaign is a tribute to them,” said Michael Singer, CEO of Careismatic Brands. “Our mission at Careismatic Brands is to champion the people behind the scrubs, and we are honored to share this very meaningful tribute as a way to thank the people who have given so much hope and professional care – at much personal risk – to so many COVID patients during these extraordinary times.”

Cavallo rerecorded the song during the middle of the pandemic’s stay-at-home mandate, so he was forced to creatively develop a process of overlaying each individual singer’s track while working remotely with engineers and musicians.

“We kept coming back to Give Me Love’s lyrics, which are incredibly meaningful and exactly what people need to hear during these unprecedented times,” Cavallo said. “George Harrison found the song to be profoundly moving and described it as a prayer and personal statement between him, the Lord and whoever likes it. If our version of this beautiful classic can brighten one nurse’s day after the incredible sacrifice they are making, it is all worth it.”

The video ends by encouraging viewers to donate to the DAISY Foundation. The fundraising effort will support their traditional programs as well as a new initiative awarding nurses grants to advance health equity in underserved communities.

“Careismatic Brands has been a longtime supporter of the DAISY Foundation and our mission to award and celebrate nurses as the unsung heroes providing quality health care,” said Bonnie Barnes, Co-Founder of the DAISY Foundation. “When we first saw the ‘Tribute to Courage’ video and heard its score with the plea for love and hope, we were immediately struck by its power and ability to provide a much-needed lift to nurses during this incredibly difficult time. We are thrilled that Careismatic Brands will be bringing this important tribute to nurses and offering a fundraising opportunity to the public,” Barnes continued. “Donations will fund nurse recognition as well as important research done by nurses to ensure that all people, no matter their race or economic situation, receive high-quality health care.”

Careismatic Brands’ “19 Days of Gratitude” campaign comes on the heels of the company’s $1 million donation of its Cherokee Uniforms and Dickies Medical branded scrubs to health care workers. The company delivered scrubs to more than 200 hospitals, in areas most impacted by the virus, to help health care workers lacking personal protective equipment get the apparel they needed to either change or even dispose of their scrubs throughout the day to avoid viral spread.

For more information on how to access the campaign, music video, 19 stories from nurses around the globe and to donate, please visit careismatic.com/TributeToCourage.

ABOUT CAREISMATIC BRANDS

Careismatic Brands, Inc. (formerly Strategic Partners, Inc.) is the global leader in medical apparel with a distribution footprint in more than 70 countries, and a deep portfolio of top-selling medical apparel, footwear and accessories brands such as Cherokee Uniforms, Dickies Medical, heartsoul, Infinity by Cherokee, ScrubStar, Tooniforms and Anywear. Plus innovative and game-changing wellbeing brands such as Certainty SmartBoost, an antimicrobial laundry additive that works alongside regular detergent to protect fabrics. Careismatic Brands’ portfolio of deeply trusted brands delivers best-in-class products and unparalleled service to distribution partners and consumers.

In addition to being the marketshare leader in medical apparel, Careismatic Brands is a manufacturer/distributor of school uniforms by Classroom, corporate identity uniforms, adaptive clothing by Silverts, medical instruments and accessories. The company takes great care to understand and provide products that champion the people wearing uniforms who serve and care for others. For more information on Careismatic Brands, visit www.careismatic.com and follow us on Facebook and Instagram.

ABOUT DAISY

The DAISY Foundation™ is the leading international organization for nursing recognition. It was created in 1999 by the family of J. Patrick Barnes, in memory of the extraordinary nursing care they experienced when he was in the hospital for 2 months with an auto-immune disease. (DAISY stands for Diseases Attacking the Immune SYstem). His family’s drive to say “thank you” to nurses for the compassionate and skillful care they provide every day – The DAISY Award® for Extraordinary Nurses – has grown to become a highly respected and international nurse recognition program. It provides unique and meaningful recognition that benefits nurses and the organizations where they work.

Today, over 4,500 healthcare organizations and schools of nursing in 29 countries are committed to honoring their nurses with The DAISY Award. Over 1.8 million nurses have been nominated by their patients, families and colleagues, and over 144,000 awards have been granted.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sara Rosales
Careismatic Brands
srosales@strategicpartners.net
310/413-2413 (mobile)

Rachel Rogers
The Acceleration
rachel.rogers@theacceleration.com
310/770-4917 (mobile)

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye